239 results on '"Gerber, Jonathan M."'
Search Results
2. Early Outpatient Treatment for Covid-19 with Convalescent Plasma
3. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations
4. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
5. Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation
6. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
7. Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination
8. Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses
9. A User’s Guide to Novel Therapies for Acute Myeloid Leukemia
10. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
11. Clonal Dynamics and Deterministic Clinical Fate Mapping of Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukemia with TP53 Disruption
12. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
13. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase
14. Natural history of clonal haematopoiesis seen in real‐world haematology settings.
15. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
16. Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
17. Cutaneous manifestations in leukemia patients
18. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
19. Early Treatment, Inflammation and Post-COVID Conditions
20. Early Treatment, Inflammation and Post-COVID Conditions
21. Prognostic Discrimination within a Heterogeneous Population of TP53-Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia
22. Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia
23. Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
24. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling
25. A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemia
26. Circulating clonotypic B cells in classic Hodgkin lymphoma
27. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
28. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia
29. Early Identification of TP53 mutation in Myelodysplastic Neoplasms and Acute Myeloid Leukemia Via Point-of-Care p53 Immunohistochemistry
30. Myeloid Derived Suppressor Cells and Their Potential Impact on Minimal Residual Disease Status and Disease Response in a Cohort of Patients with Plasma Cell Dyscrasias
31. Sole DNMT3A/TET2/ASXL1 Mutations Define a Distinct Clinical Trajectory for Patients with Clonal Hematopoiesis
32. BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
33. Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
34. Low Dose Cytoxan Mobilization – a Single Institution Experience
35. Retrospective Single Institution Comparative Study of Outcomes after Post-Transplant Cyclophosphamide for Haploidentical, Matched Unrelated, Mismatched Unrelated and Matched Sibling PB HSCT
36. Characterization of chronic myeloid leukemia stem cells
37. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia
38. Convalescent plasma therapy: A passive therapy for an aggressive COVID‐19
39. Day length affects immune cell numbers in deer mice: interactions with age, sex, and prenatal photoperiod
40. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy
41. Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
42. Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype
43. Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation
44. Survival and Time to Response with Frontline Hypomethylating Agents in AML
45. Patient Reported Financial Toxicity in Acute Leukemia
46. 516 - Low Dose Cytoxan Mobilization – a Single Institution Experience
47. 260 - Retrospective Single Institution Comparative Study of Outcomes after Post-Transplant Cyclophosphamide for Haploidentical, Matched Unrelated, Mismatched Unrelated and Matched Sibling PB HSCT
48. Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis
49. A Novel Approach to Identify a Putative Leukemia Stem Cell Population in Acute Lymphocytic Leukemia (ALL) and Distinguish Philadelphia Chromosome-Positive ALL from Lymphoid Blast Crisis Chronic Myeloid Leukemia
50. Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.